Prosecution Insights
Last updated: November 04, 2026
Application No. 18/948,163

METHODS OF ALLEVIATING SYMPTOMS OF OCULAR SURFACE DISCOMFORT USING MEDICAL ICE SLURRY

Final Rejection §103
Filed
Nov 14, 2024
Priority
Mar 27, 2020 — provisional 63/000,922 +6 more
Examiner
ARBLE, JESSICA R
Art Unit
3781
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Eyecool Therapeutics Inc.
OA Round
4 (Final)
67%
Grant Probability
Favorable
5-6
OA Rounds
1y 4m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
274 granted / 411 resolved
-3.3% vs TC avg
Strong +25% interview lift
Without
With
+25.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
37 currently pending
Career history
467
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
50.1%
+10.1% vs TC avg
§102
19.3%
-20.7% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 411 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s amendment filed 08/03/2026 is accepted and entered. Applicant’s arguments with respect to claim(s) 1 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Fremstad is now cited in the rejection to modify the device of Wong/Barken to be sized and configured to contact an ocular surface of the eye posterior to the limbus over the bulbar conjunctiva and not contact other portions of the sclera, as set forth below. Applicant did not specifically argue the dependent claims. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-6, 8, 11, and 12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wong et al (US 2007/0282282) in view of Barken (US 2021/0145500) further in view of Fremstad (US 5472436). Regarding Claim 1, Wong discloses a device (6, Figs. 2-4, 7, 10) for providing a therapeutic effect to an eye (1, Fig. 4) of a subject, the device (6, Figs. 2-4, 7, 10) comprising: a container (the walls of the shell 6 form a container that allows fluid to circulate through the shell between the fluid inlet 8 and the fluid outlet 9, Figs. 2-4, 7, 10) that is configured to contain a cold fluid (¶ [0086-0088, 0122-0125]); and one or more barriers (inner layer 20 that forms inner wall of shell 6, Figs. 2-4, 7, 10) that prevent the cold fluid from directly contacting the eye (¶ [0086-0088, 0122-0125]), wherein the one or more barriers (inner layer 20 that forms inner wall of shell 6, Figs. 2-4, 7, 10) comprise a thermally conductive metal portion that is (¶ [0086-0088, 0125]; the inner layer of the cavity can be lead or steel) configured to contact the surface of the eye (1, Figs. 2-4, 7, 10; ¶ [0086-0088, 0122-0125]). Wong is silent whether the cold fluid is a cold slurry, and whether the barrier is sized and configured to contact an ocular surface of the eye posterior to the limbus over the bulbar conjunctiva and not contact other portions of the sclera. Barken discloses a cryosurgery system, thus being in the same field of endeavor of medical cooling devices, where the cooling fluid can be a cold slurry (¶ [0044, 0050]). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the generic cold fluid of Wong to be a cold slurry, as taught by Barken. As Barken indicates that cooling fluids can be liquids, gasses, or slurries, one of ordinary skill in the art would find it obvious that a cold slurry could be utilized as the cooling fluid of Wong. Additionally, it has been held that the selection of a known material based on its suitability for its intended use supports a prima facie obviousness determination (See MPEP § 2144.07). Wong/Barken is silent whether the barrier is sized and configured to contact an ocular surface of the eye posterior to the limbus over the bulbar conjunctiva and not contact other portions of the sclera. Fremstad teaches an ocular appliance for delivering medication to the eye, thus being in the same field of endeavor of medical devices delivering a therapeutic effect to the eye, which is a ring shaped device (10, Figs. 1-3) which is sized and shaped to contact an ocular surface of the eye posterior to the limbus over the bulbar conjunctiva and not contact other portions of the sclera (Col. 3 line 37 – Col. 4 line 14). Placing the device posterior to the limbus ensures that the eye’s protective blinking mechanisms aren’t activated, and the outer circumference of the device allows it to be comfortably placed in the conjunctival sacs of the eye (Col. 3 line 37 – Col. 4 line 14). Therefore, it would have been obvious to modify the size and shape of the device of Wong/Barken to be sized and configured to contact an ocular surface of the eye posterior to the limbus over the bulbar conjunctiva and not contact other portions of the sclera, as motivated by Fremstad, to avoid preventing the eye’s protective blinking mechanisms and also allow the device to be comfortably placed within the conjunctival sacs of the eye (Col. 3 line 37 – Col. 4 line 14). Additionally, one of ordinary skill in the art would have found it obvious to modify the shape and size of the device of Wong/Barken based on the desired area of treatment, and would have found it obvious to have the size of the device allow contact with an ocular surface of the eye posterior to the limbus over the bulbar conjunctiva and not other portions of the sclera to more accurately pinpoint treatment to the specific desired portion of the eye. Regarding Claim 2, Wong/Barken/Fremstad discloses the claimed invention substantially as claimed as set forth above for Claim 1. Wong/Barken/Fremstad further discloses the ocular surface of the eye posterior to the limbus over the bulbar conjunctiva comprises a region adjacent to a corneal limbus of the eye (Wong ¶ [0123]; Fremstad Col. 3 line 37 – Col. 4 line 14). Regarding Claim 3, Wong further discloses the one or more barriers (inner layer 20 that forms inner wall of shell 6, Figs. 2-4, 7, 10) are further configured to prevent contact with a cornea of the eye (1, Figs. 2-4, 7, 10; central opening 7 prevents contact with the cornea; ¶ [0123]). Regarding Claim 4, Wong further discloses the therapeutic effect comprises hypesthesia (¶ [0122-0125]; the device is fully capable of altering the temperature of the eye to provide hypesthesia to the eye). Regarding Claim 5, Wong further discloses the container (the walls of the shell 6 form a container that allows fluid to circulate through the shell between the fluid inlet 8 and the fluid outlet 9, Figs. 2-4, 7, 10) and one or more barriers (walls that form shell 6, Figs. 2-4, 7, 10) are in the shape of a ring (as seen in Figs. 2-4, 7, 10). Regarding Claim 6, the combination of Wong/Barken/Fremstad discloses the claimed invention substantially as claimed as set forth above for Claim 1. Wong/Barken/Fremstad further discloses the device is further configured to be operable with a protective device comprising a thermally non-conductive material (the device of Wong/Barken/Fremstad is fully capable of being utilized along with a protective device comprising a thermally non-conductive material). Regarding Claim 8, the combination of Wong/Barken/Fremstad discloses the claimed invention substantially as claimed as set forth above for Claim 1. Wong/Barken/Fremstad further discloses the device is configured to cool the ocular surface for about 2 minutes to about 10 minutes (the device is fully capable of cooling the ocular surface of a subject for a period of time including for between 2 minutes and 10 minutes). Regarding Claim 11, the combination of Wong/Barken/Fremstad discloses the claimed invention substantially as claimed as set forth above for Claim 1. Wong/Barken/Fremstad discloses the device is configured to cool the ocular surface for about 4 minutes to about 15 minutes (the device is fully capable of cooling one or more areas of therapeutic effect of an eye of a subject for a period of time including for between 4 minutes and 15 minutes). Regarding Claim 12, the combination of Wong/Barken/Fremstad discloses the claimed invention substantially as claimed as set forth above for Claim 1. Wong/Barken/Fremstad discloses the device is configured to cool ocular surface to a temperature of between -6 degrees C and about 4 degrees C (Wong ¶ [0093] indicates a temperature control can be used to select the temperature of the fluid and therefore the device of Wong/Barken/Fremstad is fully capable of selecting the temperature of the cooling fluid). Claim(s) 7 is rejected under 35 U.S.C. 103 as being unpatentable over Wong et al (US 2007/0282282) in view of Barken (US 2021/0145500) further in view of Fremstad (US 5472436) further in view of Stark (US 5953097). Regarding Claim 7, Wong/Barken/Fremstad is silent whether the protective device is configured to protect a cornea of the eye. Stark teaches a contact lens for use with ophthalmic monitoring systems, thus being in the same field of endeavor of devices that can be utilized during ocular surgery, where the contact lens is configured to protect a cornea of the eye (Col. 4 lines 17-19, Fig. 3 describe a contact lens designed to cover only the patient’s cornea), where the protective device comprises a thermally non-conductive material (Col. 4 lines 27-40; polymer materials are known in the art to be thermally non-conductive). The contact lens can protect the eye/cornea during ophthalmic procedures (Col. 2 lines 22-33). Therefore, it would have been obvious to modify the device of Wong/Barken/Fremstad to be configured to be operable with a protective device comprising a thermally non-conductive material, wherein the protective device is configured to protect a cornea of the eye, as taught by Stark, to protect the eye/cornea during ophthalmic procedures such as the cryotherapy procedure of Wong/Barken/Fremstad (as motivated by Stark Col. 2 lines 22-33). Claim(s) 9 and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Wong et al (US 2007/0282282) in view of Barken (US 2021/0145500) further in view of Fremstad (US 5472436) further in view of Krolman (US 8257256). Regarding Claims 9 and 10, Wong/Barken/Fremstad is silent whether the protective device is configured to protect one or more eyelids of the eye, wherein the protective device is a speculum. Krolman teaches an eyelid speculum, thus being in the same field of endeavor of optical surgical instruments, where the eyelid speculum protects the eyelids of the eye and is made of a plastic material (Col. 2 lines 1-34; the speculum protects the eyelids by providing a physical barrier between anything applied to the eye and the eyelid by being inserted under the eyelid, and plastic materials are known in the art to be thermally non-conductive). Using an eyelid speculum holds the eyes open for surgical procedures and helps prevent eyelashes from coming in contact with the eye during the procedure (Col. 2 lines 30-34). Therefore, it would have been obvious to modify the device of Wong/Barken/Fremstad to be configured to be operable with a protective device comprising a thermally non-conductive material, where the protective device is configured to protect one or more eyelids of the eye, and wherein the protective device is a speculum, as taught by Krolman. Using an eyelid speculum holds the eyes open for surgical procedures and helps prevent eyelashes from coming in contact with the eye during the procedure (as motivated by Krolman Col. 2 lines 30-34). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jessica Arble whose telephone number is (571)272-0544. The examiner can normally be reached Mon - Fri 9 AM - 5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sarah Al-Hashimi can be reached at 571-272-7159. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JESSICA ARBLE/ Primary Examiner, Art Unit 3781
Read full office action

Prosecution Timeline

Show 7 earlier events
Oct 16, 2025
Applicant Interview (Telephonic)
Jan 28, 2026
Request for Continued Examination
Feb 19, 2026
Response after Non-Final Action
Mar 02, 2026
Non-Final Rejection mailed — §103
Jul 29, 2026
Applicant Interview (Telephonic)
Jul 30, 2026
Examiner Interview Summary
Aug 03, 2026
Response Filed
Oct 06, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766296
DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS
1y 11m to grant Granted Oct 20, 2026
Patent 12758432
NEGATIVE-PRESSURE THERAPY DRESSING WITH FLUID TRANSPORT FEATURES
3y 2m to grant Granted Oct 13, 2026
Patent 12740899
PERSONAL HYGIENE PRODUCT
4y 7m to grant Granted Sep 22, 2026
Patent 12741071
BLOOD RESERVOIR WITH BLOOD-HANDLING ASSEMBLY
2y 2m to grant Granted Sep 22, 2026
Patent 12702524
TEMPLATE AND METHOD FOR REMOVING A TATTOO THROUGH PATTERNED TRANS-EPIDERMAL PIGMENT RELEASE
5y 8m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
67%
Grant Probability
92%
With Interview (+25.1%)
3y 4m (~1y 4m remaining)
Median Time to Grant
High
PTA Risk
Based on 411 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month